EssilorLuxottica Société anonyme Full Year 2024 Earnings: EPS Misses Expectations

EssilorLuxottica Société anonyme (EPA:EL) Full Year 2024 Results

Key Financial Results

• Revenue: €26.5b (up 4.4% from FY 2023).
• Net income: €2.36b (up 3.1% from FY 2023).
• Profit margin: 8.9% (down from 9.0% in FY 2023). The decrease in margin was driven by higher expenses.
• EPS: €5.20 (up from €5.11 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

EssilorLuxottica Société anonyme EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.2%.

The primary driver behind last 12 months revenue was the Direct to Consumer segment contributing a total revenue of €14.0b (53% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to €10.3b (73% of total expenses). Explore how EL's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in France.

Performance of the French Medical Equipment industry.

The company's shares are down 3.6% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on EssilorLuxottica Société anonyme's balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.